AAP
IPSC icon

Arax Advisory Partners’s Century Therapeutics IPSC Stock Holding History

Arax Advisory Partners’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$224 Hold
99
– – ﹤0.01% 3521
2025
Q4 		$98 Hold
99
– – ﹤0.01% 3827
2025
Q3 		$49 Buy
+99
New +$53 ﹤0.01% 3532

Other funds holding IPSC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Arax Advisory Partners's IPSC Position: Q1 2026 in Review

Arax Advisory Partners held its Century Therapeutics (IPSC) position steady in Q1 2026 at 99 shares worth $224. The position accounts for ﹤0.01% of the portfolio, ranked #3521.

Arax Advisory Partners first reported a position in IPSC in Q3 2025 and has held it in 3 quarters since. 72 funds tracked by Wall St. Rank hold IPSC as of Q1 2026.

  • Arax Advisory Partners held 99 shares of Century Therapeutics worth $224 as of Q1 2026.
  • Arax Advisory Partners left its Century Therapeutics share count unchanged in Q1 2026.
  • Century Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3521 holding.
  • Arax Advisory Partners first reported a position in Century Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 72 funds tracked by Wall St. Rank held Century Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.